logo

Aveo Pharmaceuticals, Inc. (AVEO)



Trade AVEO now with
  Date
  Headline
5/8/2018 7:12:36 AM AVEO Oncology Q1 Net Loss $9.0 Mln Or $0.08/shr Vs. Net Loss $8.8 Mln Or $0.12/shr Last Year
3/13/2018 7:16:21 AM AVEO Oncology FY Net Loss $65.0 Mln Or $0.61/Shr Vs Loss Of $26.9 Mln Or $0.39/Shr Last Year
3/13/2018 7:15:33 AM AVEO Oncology 2017 Total Collaboration Revenue $7.6 Mln Vs $2.5 Mln Last Year
2/12/2018 7:07:10 AM AVEO Announces EUSA Pharma Granted Positive NICE Recommendation For FOTIVDA As First Line Treatment For ARCC
2/10/2018 11:09:35 AM AVEO Oncology, EUSA Pharma Say Encouraging Preliminary From Phase 2 Results Of TiNivo Study In Renal Cell Carcinoma
12/7/2017 7:06:51 AM AVEO Updates To Tivozanib And Ficlatuzumab Programs; Enrollment Complete In Phase 2 Portion Of Phase 1/2 TiNivo Trial
11/15/2017 4:01:43 AM EUSA Pharma And AVEO Oncology Announce First Commercial Launch Of FOTIVDA (tivozanib)
11/13/2017 10:07:53 AM B. Riley FBR Initiates AVEO Pharmaceuticals, Inc. (AVEO) At Buy With $5 Price Target
11/7/2017 7:19:26 AM AVEO Oncology Q3 Net Loss $26.4 Mln Or $0.22 Per Share
11/6/2017 4:02:17 AM AVEO Oncology, EUSA Pharma Announce Promising Phase 1 Results From Phase 1/2 TiNivo Study Of Tivozanib And Nivolumab
9/20/2017 7:13:16 AM AVEO Oncology, EUSA Pharma Announce TiNivo Combination Study Opt-in
9/13/2017 7:01:49 AM AVEO Oncology Reports Receipt Of $4 Mln R&D Payment From EUSA Pharma Related To Approval Of FOTIVDA
8/28/2017 6:18:03 AM AVEO Oncology Announces FOTIVDA Approved In EC For Advanced Renal Cell Carcinoma
8/9/2017 7:12:10 AM AVEO Oncology Q2 Net Loss $33.3 Mln Or $0.30/Shr
6/27/2017 9:06:53 AM AVEO Oncology Announces $14 Mln In Aggregate Gross Proceeds From Hercules Credit Facility
6/23/2017 8:02:08 AM AVEO Oncology Reports Positive CHMP Opinion For Tivozanib As Treatment Of Advanced Renal Cell Carcinoma
6/20/2017 7:03:11 AM AVEO Oncology Announces Pivotal Phase 3 TIVO-3 Study Of Tivozanib In Renal Cell Carcinoma Reaches Enrollment Target